Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Starting with the ABCs: Akt in breast cancer.

West KA, Dennis PA.

Mol Cancer Ther. 2011 Nov;10(11):2031. doi: 10.1158/1535-7163.MCT-11-0712. No abstract available.

2.
3.

[Nuclear receptors--watchful mistrust of tamoxifen].

Dingermann T, Zündorf I.

Pharm Unserer Zeit. 2004;33(5):350-1. German. No abstract available.

PMID:
15497327
4.

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.

Wang S, Huang X, Lee CK, Liu B.

Oncogene. 2010 Jul 22;29(29):4225-36. doi: 10.1038/onc.2010.180. Epub 2010 May 24.

PMID:
20498641
5.

Targeting antihormone resistance in breast cancer: a simple solution.

Jordan VC.

Ann Oncol. 2003 Jul;14(7):969-70. No abstract available.

PMID:
12853334
6.

Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.

Rayala SK, Kumar R.

Biomed Pharmacother. 2007 Aug;61(7):408-11. Epub 2007 Jun 12. Review.

PMID:
17604944
7.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

Ghayad SE, Cohen PA.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.

PMID:
19751211
8.

Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.

Arteaga CL, Koli KM, Dugger TC, Clarke R.

J Natl Cancer Inst. 1999 Jan 6;91(1):46-53.

PMID:
9890169
9.
10.

Pak up your breast tumor--and grow!

Jordan VC.

J Natl Cancer Inst. 2006 May 17;98(10):657-9. No abstract available.

PMID:
16705113
11.

Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells.

Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K.

Breast Cancer Res Treat. 1997 Jan;42(1):73-81.

PMID:
9116321
12.

Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity.

Rayala SK, Molli PR, Kumar R.

Cancer Res. 2006 Jun 15;66(12):5985-8. Review.

13.

Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer.

Butt AJ.

Cancer Biol Ther. 2011 Jun 1;11(11):947-9. Epub 2011 Jun 1. No abstract available.

PMID:
21577052
14.

Cancer: survival pathways meet their end.

McCormick F.

Nature. 2004 Mar 18;428(6980):267-9. No abstract available.

PMID:
15029179
15.

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.

Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.

J Natl Cancer Inst. 2006 May 17;98(10):671-80.

PMID:
16705121
16.

Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.

Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H.

Cancer Biol Ther. 2005 Sep;4(9):956-60. Epub 2005 Sep 13.

PMID:
16082189
17.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
18.

Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?

Lilling G, Hacohen H, Nordenberg J, Livnat T, Rotter V, Sidi Y.

Cancer Lett. 2000 Dec 8;161(1):27-34.

PMID:
11078910
19.

Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling.

Yeh CT, Wu CH, Yen GC.

Mol Nutr Food Res. 2010 Sep;54(9):1285-95. doi: 10.1002/mnfr.200900414. Erratum in: Mol Nutr Food Res.2010 Nov;54(11):1696.

PMID:
20352621
20.

Supplemental Content

Support Center